Virovek

Virovek is a private, US-based company providing viral vector technology and manufacturing services, primarily focused on AAV production for gene therapy. Its core innovation is the proprietary BAC-to-AAV platform, which claims to generate up to 1e17 viral genomes per batch, offering significant scalability and efficiency advantages. The company operates a service-based business model, offering custom and off-the-shelf vectors to over 100 research and industry partners, positioning it as a critical enabler in the growing gene therapy sector.

Patented BAC-to-AAV technology for large-scale, high-yield production of adeno-associated virus (AAV) vectors. Also offers AdONE system for adenovirus production.

Virovek competes with large, established CDMOs (e.g., Lonza, Catalent, Thermo Fisher) that offer viral vector manufacturing, as well as specialized biotech firms developing alternative AAV production platforms (e.g., triple transfection, insect cell systems). Its differentiation hinges on the claimed yield and efficiency of its proprietary BAC-to-AAV system.